Loading…
Heart Transplant with Donor-Specific Antibody after Immunoadsorption plus Rituximab: A Case Report
Different desensitization strategies are available for treating patients with preformed human leukocyte antigen (HLA) antibodies. A highly presensitized heart recipient received immunoadsorption and rituximab therapy. The patient, with end-stage heart failure, was positive only for antibodies of HLA...
Saved in:
| Published in: | Progress in transplantation (Aliso Viejo, Calif.) Calif.), 2013-06, Vol.23 (2), p.128-131 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c347t-d03f7076b417e03a1274f977d26386a36acca77d24be4f5d9dbe46ceb7c091d03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c347t-d03f7076b417e03a1274f977d26386a36acca77d24be4f5d9dbe46ceb7c091d03 |
| container_end_page | 131 |
| container_issue | 2 |
| container_start_page | 128 |
| container_title | Progress in transplantation (Aliso Viejo, Calif.) |
| container_volume | 23 |
| creator | Resse, Marianna Maiello, Ciro Cacciatore, Francesco Romano, Gianpaolo Sabia, Chiara Picascia, Antonietta Ursomando, Fabio Napoli, Claudio |
| description | Different desensitization strategies are available for treating patients with preformed human leukocyte antigen (HLA) antibodies. A highly presensitized heart recipient received immunoadsorption and rituximab therapy. The patient, with end-stage heart failure, was positive only for antibodies of HLA class I (anti-A2, A10, B17), and Luminex platform (One Lambda kit) showed a panel-reactive antibody score of 64%. The patient's serum was tested repeatedly in both complement-dependent cytotoxicity and flow-cytometry crossmatches against cells from different potential organ donors. The results of these crossmatches were positive on flow cytometry when tested with HLA-A2, A10, and B17 but were still negative on cytotoxicity. The patient was treated with a desensitization regimen; this treatment immediately decreased antibody levels of 70% and the patient subsequently received a transplant with donor-specific HLA antibody (HLA-A2). After more than 2 years, graft function remains normal and the clinical status of the patient is stable. |
| doi_str_mv | 10.7182/pit2013454 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1370633950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.7182_pit2013454</sage_id><sourcerecordid>1370633950</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-d03f7076b417e03a1274f977d26386a36acca77d24be4f5d9dbe46ceb7c091d03</originalsourceid><addsrcrecordid>eNplkN1LwzAUxYMoOqcv_gES8EERqvlq0vo25seEgTDnc0nTVCNrU5MU3X9vxuYH-nS58LvnnnMAOMLoQuCMXHYmEIQpS9kWGBDMWcIFyrbBAKeEJzlh2R7Y9_4VISJYhnbBHqEiIzzNB6CcaOkCnDvZ-m4h2wDfTXiB17a1LnnstDK1UXDUBlPaagllHbSD903Tt1ZW3rouGNvCbtF7ODOh_zCNLK_gCI6l13CmO-vCAdip5cLrw80cgqfbm_l4kkwf7u7Ho2miKBMhqRCtBRK8ZFhoRCWOZutciIpwmnFJuVRKrlZWalanVV7FyZUuhUI5jtdDcLbW7Zx967UPRWO80ouYStveF5gKxCnN0xV68gd9tb1ro7sCpxwjLtJcROp8TSlnvXe6LjoX87llgVGxar74aT7CxxvJvmx09Y1-VR2B0zXg5bP-9e-_1CfswIrP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1561067597</pqid></control><display><type>article</type><title>Heart Transplant with Donor-Specific Antibody after Immunoadsorption plus Rituximab: A Case Report</title><source>Sage Journals Online</source><creator>Resse, Marianna ; Maiello, Ciro ; Cacciatore, Francesco ; Romano, Gianpaolo ; Sabia, Chiara ; Picascia, Antonietta ; Ursomando, Fabio ; Napoli, Claudio</creator><creatorcontrib>Resse, Marianna ; Maiello, Ciro ; Cacciatore, Francesco ; Romano, Gianpaolo ; Sabia, Chiara ; Picascia, Antonietta ; Ursomando, Fabio ; Napoli, Claudio</creatorcontrib><description>Different desensitization strategies are available for treating patients with preformed human leukocyte antigen (HLA) antibodies. A highly presensitized heart recipient received immunoadsorption and rituximab therapy. The patient, with end-stage heart failure, was positive only for antibodies of HLA class I (anti-A2, A10, B17), and Luminex platform (One Lambda kit) showed a panel-reactive antibody score of 64%. The patient's serum was tested repeatedly in both complement-dependent cytotoxicity and flow-cytometry crossmatches against cells from different potential organ donors. The results of these crossmatches were positive on flow cytometry when tested with HLA-A2, A10, and B17 but were still negative on cytotoxicity. The patient was treated with a desensitization regimen; this treatment immediately decreased antibody levels of 70% and the patient subsequently received a transplant with donor-specific HLA antibody (HLA-A2). After more than 2 years, graft function remains normal and the clinical status of the patient is stable.</description><identifier>ISSN: 1526-9248</identifier><identifier>EISSN: 2164-6708</identifier><identifier>DOI: 10.7182/pit2013454</identifier><identifier>PMID: 23782659</identifier><identifier>CODEN: PTRRBT</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Antibodies, Monoclonal, Murine-Derived - administration & dosage ; Antibodies, Monoclonal, Murine-Derived - immunology ; Desensitization, Immunologic - methods ; Flow Cytometry ; Graft Survival ; Heart Transplantation - immunology ; Histocompatibility Testing - methods ; HLA-A Antigens - immunology ; Humans ; Immunoglobulins - administration & dosage ; Immunologic Factors - administration & dosage ; Immunosorbents - therapeutic use ; Isoantibodies - immunology ; Male ; Nursing ; Rituximab</subject><ispartof>Progress in transplantation (Aliso Viejo, Calif.), 2013-06, Vol.23 (2), p.128-131</ispartof><rights>2013 NATCO: The Organization for Transplant Professionals</rights><rights>Copyright North American Transplant Coordinators Organization Jun 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-d03f7076b417e03a1274f977d26386a36acca77d24be4f5d9dbe46ceb7c091d03</citedby><cites>FETCH-LOGICAL-c347t-d03f7076b417e03a1274f977d26386a36acca77d24be4f5d9dbe46ceb7c091d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23782659$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Resse, Marianna</creatorcontrib><creatorcontrib>Maiello, Ciro</creatorcontrib><creatorcontrib>Cacciatore, Francesco</creatorcontrib><creatorcontrib>Romano, Gianpaolo</creatorcontrib><creatorcontrib>Sabia, Chiara</creatorcontrib><creatorcontrib>Picascia, Antonietta</creatorcontrib><creatorcontrib>Ursomando, Fabio</creatorcontrib><creatorcontrib>Napoli, Claudio</creatorcontrib><title>Heart Transplant with Donor-Specific Antibody after Immunoadsorption plus Rituximab: A Case Report</title><title>Progress in transplantation (Aliso Viejo, Calif.)</title><addtitle>Prog Transplant</addtitle><description>Different desensitization strategies are available for treating patients with preformed human leukocyte antigen (HLA) antibodies. A highly presensitized heart recipient received immunoadsorption and rituximab therapy. The patient, with end-stage heart failure, was positive only for antibodies of HLA class I (anti-A2, A10, B17), and Luminex platform (One Lambda kit) showed a panel-reactive antibody score of 64%. The patient's serum was tested repeatedly in both complement-dependent cytotoxicity and flow-cytometry crossmatches against cells from different potential organ donors. The results of these crossmatches were positive on flow cytometry when tested with HLA-A2, A10, and B17 but were still negative on cytotoxicity. The patient was treated with a desensitization regimen; this treatment immediately decreased antibody levels of 70% and the patient subsequently received a transplant with donor-specific HLA antibody (HLA-A2). After more than 2 years, graft function remains normal and the clinical status of the patient is stable.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Murine-Derived - administration & dosage</subject><subject>Antibodies, Monoclonal, Murine-Derived - immunology</subject><subject>Desensitization, Immunologic - methods</subject><subject>Flow Cytometry</subject><subject>Graft Survival</subject><subject>Heart Transplantation - immunology</subject><subject>Histocompatibility Testing - methods</subject><subject>HLA-A Antigens - immunology</subject><subject>Humans</subject><subject>Immunoglobulins - administration & dosage</subject><subject>Immunologic Factors - administration & dosage</subject><subject>Immunosorbents - therapeutic use</subject><subject>Isoantibodies - immunology</subject><subject>Male</subject><subject>Nursing</subject><subject>Rituximab</subject><issn>1526-9248</issn><issn>2164-6708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNplkN1LwzAUxYMoOqcv_gES8EERqvlq0vo25seEgTDnc0nTVCNrU5MU3X9vxuYH-nS58LvnnnMAOMLoQuCMXHYmEIQpS9kWGBDMWcIFyrbBAKeEJzlh2R7Y9_4VISJYhnbBHqEiIzzNB6CcaOkCnDvZ-m4h2wDfTXiB17a1LnnstDK1UXDUBlPaagllHbSD903Tt1ZW3rouGNvCbtF7ODOh_zCNLK_gCI6l13CmO-vCAdip5cLrw80cgqfbm_l4kkwf7u7Ho2miKBMhqRCtBRK8ZFhoRCWOZutciIpwmnFJuVRKrlZWalanVV7FyZUuhUI5jtdDcLbW7Zx967UPRWO80ouYStveF5gKxCnN0xV68gd9tb1ro7sCpxwjLtJcROp8TSlnvXe6LjoX87llgVGxar74aT7CxxvJvmx09Y1-VR2B0zXg5bP-9e-_1CfswIrP</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Resse, Marianna</creator><creator>Maiello, Ciro</creator><creator>Cacciatore, Francesco</creator><creator>Romano, Gianpaolo</creator><creator>Sabia, Chiara</creator><creator>Picascia, Antonietta</creator><creator>Ursomando, Fabio</creator><creator>Napoli, Claudio</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>201306</creationdate><title>Heart Transplant with Donor-Specific Antibody after Immunoadsorption plus Rituximab: A Case Report</title><author>Resse, Marianna ; Maiello, Ciro ; Cacciatore, Francesco ; Romano, Gianpaolo ; Sabia, Chiara ; Picascia, Antonietta ; Ursomando, Fabio ; Napoli, Claudio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-d03f7076b417e03a1274f977d26386a36acca77d24be4f5d9dbe46ceb7c091d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Murine-Derived - administration & dosage</topic><topic>Antibodies, Monoclonal, Murine-Derived - immunology</topic><topic>Desensitization, Immunologic - methods</topic><topic>Flow Cytometry</topic><topic>Graft Survival</topic><topic>Heart Transplantation - immunology</topic><topic>Histocompatibility Testing - methods</topic><topic>HLA-A Antigens - immunology</topic><topic>Humans</topic><topic>Immunoglobulins - administration & dosage</topic><topic>Immunologic Factors - administration & dosage</topic><topic>Immunosorbents - therapeutic use</topic><topic>Isoantibodies - immunology</topic><topic>Male</topic><topic>Nursing</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Resse, Marianna</creatorcontrib><creatorcontrib>Maiello, Ciro</creatorcontrib><creatorcontrib>Cacciatore, Francesco</creatorcontrib><creatorcontrib>Romano, Gianpaolo</creatorcontrib><creatorcontrib>Sabia, Chiara</creatorcontrib><creatorcontrib>Picascia, Antonietta</creatorcontrib><creatorcontrib>Ursomando, Fabio</creatorcontrib><creatorcontrib>Napoli, Claudio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in transplantation (Aliso Viejo, Calif.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Resse, Marianna</au><au>Maiello, Ciro</au><au>Cacciatore, Francesco</au><au>Romano, Gianpaolo</au><au>Sabia, Chiara</au><au>Picascia, Antonietta</au><au>Ursomando, Fabio</au><au>Napoli, Claudio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heart Transplant with Donor-Specific Antibody after Immunoadsorption plus Rituximab: A Case Report</atitle><jtitle>Progress in transplantation (Aliso Viejo, Calif.)</jtitle><addtitle>Prog Transplant</addtitle><date>2013-06</date><risdate>2013</risdate><volume>23</volume><issue>2</issue><spage>128</spage><epage>131</epage><pages>128-131</pages><issn>1526-9248</issn><eissn>2164-6708</eissn><coden>PTRRBT</coden><abstract>Different desensitization strategies are available for treating patients with preformed human leukocyte antigen (HLA) antibodies. A highly presensitized heart recipient received immunoadsorption and rituximab therapy. The patient, with end-stage heart failure, was positive only for antibodies of HLA class I (anti-A2, A10, B17), and Luminex platform (One Lambda kit) showed a panel-reactive antibody score of 64%. The patient's serum was tested repeatedly in both complement-dependent cytotoxicity and flow-cytometry crossmatches against cells from different potential organ donors. The results of these crossmatches were positive on flow cytometry when tested with HLA-A2, A10, and B17 but were still negative on cytotoxicity. The patient was treated with a desensitization regimen; this treatment immediately decreased antibody levels of 70% and the patient subsequently received a transplant with donor-specific HLA antibody (HLA-A2). After more than 2 years, graft function remains normal and the clinical status of the patient is stable.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>23782659</pmid><doi>10.7182/pit2013454</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1526-9248 |
| ispartof | Progress in transplantation (Aliso Viejo, Calif.), 2013-06, Vol.23 (2), p.128-131 |
| issn | 1526-9248 2164-6708 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1370633950 |
| source | Sage Journals Online |
| subjects | Adult Antibodies, Monoclonal, Murine-Derived - administration & dosage Antibodies, Monoclonal, Murine-Derived - immunology Desensitization, Immunologic - methods Flow Cytometry Graft Survival Heart Transplantation - immunology Histocompatibility Testing - methods HLA-A Antigens - immunology Humans Immunoglobulins - administration & dosage Immunologic Factors - administration & dosage Immunosorbents - therapeutic use Isoantibodies - immunology Male Nursing Rituximab |
| title | Heart Transplant with Donor-Specific Antibody after Immunoadsorption plus Rituximab: A Case Report |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T23%3A03%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heart%20Transplant%20with%20Donor-Specific%20Antibody%20after%20Immunoadsorption%20plus%20Rituximab:%20A%20Case%20Report&rft.jtitle=Progress%20in%20transplantation%20(Aliso%20Viejo,%20Calif.)&rft.au=Resse,%20Marianna&rft.date=2013-06&rft.volume=23&rft.issue=2&rft.spage=128&rft.epage=131&rft.pages=128-131&rft.issn=1526-9248&rft.eissn=2164-6708&rft.coden=PTRRBT&rft_id=info:doi/10.7182/pit2013454&rft_dat=%3Cproquest_cross%3E1370633950%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c347t-d03f7076b417e03a1274f977d26386a36acca77d24be4f5d9dbe46ceb7c091d03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1561067597&rft_id=info:pmid/23782659&rft_sage_id=10.7182_pit2013454&rfr_iscdi=true |